Jaypirca (pirtobrutinib tablets) — Cigna
Marginal Zone Lymphoma
Initial criteria
- Patient age ≥ 18 years AND
- Patient has tried at least one Bruton tyrosine kinase (BTK) inhibitor (e.g., Calquence [acalabrutinib], Brukinsa [zanubrutinib], Imbruvica [ibrutinib])
Approval duration
1 year